Financial Performance - For the six months ended June 30, 2023, the net loss was $82.1 million, compared to a net loss of $5.8 million for the same period in 2022, reflecting a significant increase in operating losses [97]. - The company recorded a pre-tax net loss of $86.3 million for the three months ended June 30, 2023, compared to a pre-tax net loss of $2.0 million for the same period in 2022, indicating a substantial increase in losses [112]. - The company incurred a net loss of $82.1 million for the six months ended June 30, 2023, compared to a net loss of $5.8 million for the same period in 2022, resulting in an accumulated deficit of $87.0 million [128]. Expenses - Research and development expenses for the three months ended June 30, 2023, were $1.2 million, an increase of 69.7% from $0.7 million in the same period in 2022, primarily due to increased manufacturing costs for IC 100 [113]. - General and administrative expenses for the three months ended June 30, 2023, were $3.9 million, a 237.5% increase from $1.2 million in the same period in 2022, driven by stock grants and increased professional fees [114]. - Total operating expenses for the three months ended June 30, 2023, were $86.3 million, a dramatic increase of 4338.6% compared to $1.9 million in the same period in 2022 [112]. - Research and development expenses increased to $2.3 million for the six months ended June 30, 2023, up $0.5 million or 27.4% from the same period in 2022 [119]. - General and administrative expenses rose to $7.5 million, an increase of $4.0 million or 115.4% compared to the prior year, primarily due to stock grants and professional fees [120]. - Impairment of in-process research and development was $69.3 million for the three months ended June 30, 2023, compared to none in the same period in 2022, due to a decline in stock value [115]. - Impairment of in-process research and development and goodwill totaled $69.3 million and $11.9 million, respectively, compared to none in the prior year, reflecting a decline in stock value [121]. Cash Flow and Financing - Net cash used in operating activities was $5.0 million for the six months ended June 30, 2023, compared to $0.7 million in the same period of 2022, driven by a net loss of approximately $82.1 million [124]. - Cash provided by financing activities was negative $0.7 million for the six months ended June 30, 2023, primarily due to the redemption of Series A Preferred Stock [125]. - The company will seek additional financing through public or private equity or debt financings to support its operations, as adequate financing may not be available on acceptable terms [98]. - The company plans to raise additional capital to fund operations and the development of product candidates VAR200 and IC100 [131]. - Future operations depend on successful capital raising efforts, as the current cash balance is only sufficient for month-to-month operational expenses [128]. Current Assets and Liabilities - Current assets decreased to $1.1 million as of June 30, 2023, from $6.4 million at the end of 2022, while current liabilities increased to $10.5 million [127]. - The company had an accumulated deficit of approximately $87.0 million as of June 30, 2023, with cash reserves of only $0.2 million [97]. - The company has significant contractual obligations totaling approximately $10.5 million for accounts payable and accrued expenses as of June 30, 2023 [129]. Future Outlook - The company has not generated any revenue to date and does not expect to do so in the near future, relying on future collaborations or regulatory approvals for potential revenue [99]. - The company anticipates continued significant expenses related to ongoing research and development activities, which are expected to increase as clinical trials progress [103].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number: 001-41184 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 86-2685744 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number: 001-41184 ZYVERSA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 86-2685744 (State ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-41184 LARKSPUR HEALTH ACQUISITION CORP. (Exact name of registrant as specified in its charter) Delawa ...

Financial Performance - The company reported a net loss of $393,639 for the three-month period ended June 30, 2022, primarily due to formation and operating costs of $498,751, partially offset by interest income of $105,113 [111]. - For the six-month period ended June 30, 2022, the net loss was $1,113,645, consisting of formation and operating costs of $1,299,800, offset by interest income of $109,567 and a change in fair value of derivative liability of $76,588 [111]. - Cash used in operating activities for the six months ended June 30, 2022, was $588,350, primarily due to the net loss [123]. - The diluted net loss per common share is the same as the basic net loss per common share due to the absence of dilutive securities as of June 30, 2022 [131]. Capital Raising and Liquidity - The company completed its IPO on December 23, 2021, raising gross proceeds of $75,000,000 from the sale of 7,500,000 units at $10.00 per unit [112]. - An additional $2,698,306 was raised from the exercise of the underwriters' over-allotment option, bringing total gross proceeds to $77,698,306 [114]. - The company has approximately $1,250,000 available outside the trust account for identifying and evaluating target businesses and conducting due diligence [116]. - Estimated primary liquidity requirements include $425,000 for legal and accounting expenses, $600,000 for D&O insurance, and $150,000 for regulatory reporting fees [118]. - The company intends to use substantially all funds in the trust account to complete its initial business combination [115]. Debt and Going Concern - The company does not have any long-term debt obligations or capital lease obligations [124]. - There is substantial doubt about the company's ability to continue as a going concern within one year after the issuance of the financial statements [122]. Stockholder Rights and Securities - The company has agreed to waive redemption rights for founder shares in connection with business combinations and stockholder votes, with a potential extension of up to 18 months from the IPO closing [127]. - The company is required to register certain securities for sale under the Securities Act, allowing initial stockholders to make up to three demands for registration [128]. - As of June 30, 2022, the company reported Class A common stock subject to possible redemption amounting to $78,448,306, classified as temporary equity [133]. Accounting and Market Risk - The company has no identified critical accounting policies or estimates that could materially differ from actual results [129]. - The company evaluates its financial instruments to determine if they qualify as derivatives, with changes in fair value reported in the statements of operations [132]. - The company has not disclosed any market risk information as it qualifies as a smaller reporting company [134].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-41184 LARKSPUR HEALTH ACQUISITION CORP. (Exact name of registrant as specified in its charter) | Delaware ...

Financial Performance - The company reported a net loss of $240,700 for the period from March 17, 2021, through December 31, 2021, primarily due to operating and formation costs of $235,267[144]. - The company has not generated any revenues since its inception on March 17, 2021, and has engaged in limited operations[167]. Cash and Capital Structure - As of December 31, 2021, the company had $928,389 in cash and a working capital of $903,354[145]. - A total of $75,750,000 from the IPO proceeds was placed in a trust account for the purpose of completing the initial business combination[148]. - The net proceeds from the IPO and private placement warrants are held in a trust account and invested in U.S. government treasury bills or money market funds[168]. Initial Public Offering (IPO) - The initial public offering (IPO) generated gross proceeds of $75,000,000 from the sale of 7,500,000 units, with each unit priced at $10.00[146]. - A private placement with sponsors generated an additional $3,176,000 from the sale of 317,600 units at the same price of $10.00 per unit[147]. - Sponsors purchased an aggregate of 320,272 private units at a price of $10.00 per unit for a total of $3,202,720[162]. Business Combination and Future Expectations - The company expects to incur approximately $425,000 for legal, accounting, and due diligence expenses related to business combinations, along with $600,000 for D&O insurance[152]. - The company anticipates annual franchise tax obligations of $200,000, which will be paid from funds held outside the trust account or from interest earned on the trust account[149]. - The company may need to seek additional financing to complete its initial business combination if the target businesses exceed the net proceeds from the IPO[154]. - The company may extend the business combination deadline up to 18 months from the IPO closing, requiring a deposit of $776,716 ($0.10 per unit) for each three-month extension[162]. - Initial stockholders will have redemption rights for public shares if a business combination is not completed within 12 months (or up to 18 months) from the IPO[163]. Going Concern and Risks - There is substantial doubt about the company's ability to continue as a going concern within one year after the issuance of the financial statements[155]. - The company has not engaged in any operations or generated revenues to date, with expectations to incur increased expenses post-IPO[143]. Corporate Governance - The board of directors consists of five members, including the CEO and three independent directors, with voting rights limited to Class B common stock holders until the initial business combination is completed[161]. Regulatory and Compliance - The company qualifies as an "emerging growth company" under the JOBS Act, allowing it to delay the adoption of new accounting standards[165]. - The company may not be required to provide certain disclosures related to executive compensation for five years following the IPO[166]. Market and Risk Management - The company does not expect to engage in any hedging activities related to market risk[167]. - Each whole warrant is exercisable to purchase one whole share of Class A common stock at $11.50 per share[162].